Arax Advisory Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Arax Advisory Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$188K	Buy	7,436 +7,304	+5,533%	+$161K	﹤0.01%	2292
2026 Q1	$2.87K	Sell	132 -95	-42%	-$2.27K	﹤0.01%	2994
2025 Q4	$6.06K	Sell	227 -19,392	-99%	-$463K	﹤0.01%	2745
2025 Q3	$419K	Buy	+19,619	New	+$464K	0.01%	976
2025 Q2	–	Sell	-174	Closed	-$2.89K	–	3031
2025 Q1	$2.89K	Buy	174 +129	+287%	+$2.34K	﹤0.01%	1964
2024 Q4	$826	Buy	45 +1	+2%	+$16	﹤0.01%	2213
2024 Q3	$677	Hold	44	–	–	﹤0.01%	2350
2024 Q2	$715	Buy	+44	New	+$710	﹤0.01%	2262

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arax Advisory Partners's ACAD Position: Q2 2026 in Review

Arax Advisory Partners increased its Acadia Pharmaceuticals (ACAD) stake by 5,533% in Q2 2026, buying an estimated $161K and bringing the position to 7,436 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #2292.

Arax Advisory Partners first reported a position in ACAD in Q2 2024 and has held it in 8 quarters since. The position peaked at $419K in Q3 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Arax Advisory Partners held 7,436 shares of Acadia Pharmaceuticals worth $188K as of Q2 2026.
Arax Advisory Partners bought 7,304 Acadia Pharmaceuticals shares in Q2 2026, an estimated $161K.
Acadia Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2292 holding.
Arax Advisory Partners first reported a position in Acadia Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Arax Advisory Partners's Acadia Pharmaceuticals position peaked at $419K in Q3 2025.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.